ubenimex has been researched along with busulfan in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saito, Y; Usuka, Y | 1 |
| Saito, Y; Uzuka, Y | 2 |
| Fujimaki, K; Ishigatsubo, Y; Kanamori, H; Koharazawa, H; Taguchi, J; Takabayashi, M; Takasaki, H; Yamaji, S | 1 |
4 other study(ies) available for ubenimex and busulfan
| Article | Year |
|---|---|
Bestatin treatment of myelodysplastic syndromes and chronic myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Drug Therapy, Combination; Female; Humans; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes | 1991 |
[Combination therapy of chronic myelogenous leukemia with busulfan and bestatin].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Gene Rearrangement; Humans; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Remission Induction | 1991 |
[Bestatin therapy of chronic myelogenous leukemia].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Humans; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Remission Induction; Survival Rate | 1993 |
Long-term cytogenetic remission with ubenimex monotherapy in a case of chronic myeloid leukemia.
Topics: Aged; Bone Marrow Cells; Busulfan; Humans; Immunologic Factors; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Remission Induction; Time Factors | 2004 |